.png)
.png)
ValiRx seals deal to license late-stage cancer therapy
ValiRx Plc, a life science company focusing on cancer therapeutics and women's health, has announced that ValiRx subsidiary, ValiSeek Ltd, has entered into an exclusive option agreement to license VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company.
Arecor strikes co-development deal for specialty hospital product
Arecor-developed, Arestat™-enabled product is potentially first ready-to-dilute liquid formulation of a high-value oncology therapy
CEO Update - 4 December 2023
UK Biobank is a British success story that puts us at the heart of a key global technology of this century. Last week, UK Biobank published the world’s largest collection of full human genomes. Set up 20 years ago, the charity UK Biobank recruited half a million altruistic volunteers to create the world’s most comprehensive source of health data.
bioProcessUK 2023: Honouring excellence, unveiling future leaders
In a symphony of innovation and camaraderie, the 20th anniversary bioProcessUK conference swept through Brighton, creating an unforgettable experience for the life sciences and biotech community.
Discovery Park Ventures expands fund to fuel UK Sci-Tech Startups
Discovery Park Ventures (DPV) announces the expansion of its early-stage life science fund from £1million to £3 million, in order to capitalise on exciting investment opportunities and support its existing portfolio.
Vast West Midlands laboratory poised to propel UK life sciences
The Rosalind Franklin Laboratory, a state-of-the-art, fully fitted CL2 lab facility in Leamington Spa, Warwickshire, has come to market, with global real estate advisor, Avison Young, promoting it as an ‘unmissable opportunity’ for the UK life sciences sector.
Arecor continues collaboration with Lilly
Development of an enhanced formulation of Lilly proprietary product using Arecor’s formulation technology platform Arestat™
Hartmut van Lengerich appointed as Chairman of Moa Technology
With over 30 years’ experience in global strategic and operational roles, including serving as Bayer Crop Science’s CEO for Canada, Global Head of Cereals, Head of Fungicides and, most recently, SVP Global Crop Protection Asset Management at Bayer AG, overseeing $13bn in worldwide sales
ACROBiosystems launches the world’s first GMP-grade DLL-4 Protein
ACROBiosystems, a global cornerstone of the pharmaceutical industry committed to offering innovative tools and solutions, announces the launch of GMP grade DLL4. GMP grade DLL4 is the first recombinant Delta-like Ligand 4, or DLL4, to be launched on the market under GMP conditions.
Investors-in-residence join Cancer Research Horizons to advance Ventures team
Jonathan Tobin, a partner at life science venture capital firm Brandon Capital, and Genghis Lloyd-Harris, a senior advisor at life sciences investment firm, Abingworth, have joined Cancer Research Horizons’ Ventures team as advisory investors-in-residence.